Improved myocardial perfusion preceding clinical response on bosentan treatment for coronary vasospasm.Vermeltfoort, I. A. C., Raijmakers, P. G. H. M. & Kamphuisen, P. W., 1-Jun-2009, In : Acta cardiologica. 64, 3, p. 415-417 3 p.
Research output: Contribution to journal › Article › Academic › peer-review
Many patients suffer from persistent angina due to coronary vasospasm despite optimal medical treatment. We treated a 46-year-old patient with severe and treatment-resistant coronary vasospasm with the endothelin-receptor antagonist bosentan. Using oxygen-15-labelled water in conjunction with oxygen 15-labelled carbon monoxide positron emission tomography (PET), we measured an impaired coronary flow reserve (CFR) in 6 out of 13 segments directly before the start of bosentan therapy. A repeated PET measurement after 16 weeks of bosentan revealed a completely normalized CFR in this patient. Furthermore, the patient reported less frequent and less severe chest pain. Our data suggest a potential role of endothelin-receptor antagonists for patients with severe coronary vasospasms.
|Number of pages||3|
|Publication status||Published - 1-Jun-2009|
- antihypertensive agent, bosentan, sulfonamide, article, blood flow velocity, case report, coronary artery spasm, fractional flow reserve, human, male, middle aged, myocardial perfusion imaging, pathophysiology, positron emission tomography, variant angina pectoris